ENGINEERED ANTI-ALPHA V- INTEGRIN HYBRID ANTIBODIES

The invention relates to engineered antibodies which specifically bind to integrin recepors, especially the alpha V integrin receptor subunit. The antibodies comprise the antigen binding sites (CDRs) of a known mouse anti-integrin antibody, as well as hybrid light chain variable sequences, mutated h...

Full description

Saved in:
Bibliographic Details
Main Authors LO KIN-MING, ADAN JAUME, MITJANS FRANCESC, GOODMAN SIMON, HAHN DIANE
Format Patent
LanguageEnglish
Slovenian
Published 31.01.2013
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The invention relates to engineered antibodies which specifically bind to integrin recepors, especially the alpha V integrin receptor subunit. The antibodies comprise the antigen binding sites (CDRs) of a known mouse anti-integrin antibody, as well as hybrid light chain variable sequences, mutated heavy chain variable sequences (Frs) and modified heavy chain constant sequences. The novel antibodies have improved immunogenic and expression properties and elicit excellent anti-angiogenic as well as anti-tumor activities in humans in monotherapy but also and above all in combination with other angiogenesis and tumor inhibiting agents.
Bibliography:Application Number: SI20080030845T